Catalyst Biosciences Sells Drug Asset for $37.75 Million
By

By
Catalyst Biosciences, a South San Francisco, California-based clinical-stage biopharmaceutical company, has entered into a definitive agreement to sell one of its neuronal nicotinic receptor (NNR) assets that were under development…

Allergan Gets Antitrust OK for $639 Million Acquisition of Vitae Pharma
By

By
Allergan has announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan’s pending acquisition of Vitae Pharmaceuticals, a…

RXi Agrees to Acquire MirImmune
By

By
RXi Pharmaceuticals, a clinical-stage RNAi company based in Marlborough, Massachusetts, has agreed to acquire all outstanding capital stock of MirImmune, a Cambridge, Massachusetts-based immunotherapy company, in consideration for a number…

Roche Leads New Drug Approvals
By

By
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Roche.  Editor’s Note: This article is updated on a continuous basis for news announced from Wednesday October…

AbbVie, AstraZeneca, BMS, Novo Nordisk, and Teva Lead Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring news from AbbVie, AstraZeneca, BMS, Novo Nordisk, and Teva.  Editor’s Note: This…

Astellas Partners to Develop Anti-Doping Drugs
By

By
Astellas Pharma and the World Anti-Doping Agency (WADA) have agreed to partner to prevent the misuse and abuse of medicines for doping in sports. Doping in sports relies primarily on…

Regeneron, Ocular Therapeutix Collaborate on Eye Care Drugs
By

By
Ocular Therapeutix, a Bedford, Massachusetts-based biopharmaceutical company developing therapies for diseases and conditions of the eye, has formed a strategic collaboration, worth up to $315 million, including an option and license…

Vertex Expands CF Foundation Therapeutics Partnership
By

By
Vertex Pharmaceuticals has expanded its long-term research and development collaboration with Cystic Fibrosis Foundation Therapeutics (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation (CFF), under…

Pfizer Launches Biosimilar to J&J’s Remicade
By

By
Pfizer has launched Inflectra (infliximab-dyyb) for injection, a biosimilar of Johnson & Johnson’s (J&J) anti-inflammatory drug, Remicade (infliximab), and will begin shipment of Inflectra to wholesalers in the US in…

Merck KGaA Expands Biotech Production Capacity in Spain
By

By
Merck KGaA, has completed an expansion of its biotech plant in Tres Cantos, Madrid, Spain, resulting in a 50% increase in the facility’s production capacity. Tres Cantos is the main…